The study was approved by the local ethics committee and all patients gave written informed consent. Epirubicin pharmacokinetics were studied in 32 women with advanced breast cancer who had received no prior anthracycline treatment. Pharmacokinetics were studied during their first cycle of chemotherapy. All patients had normal liver biochemistry with serum aspartate aminotransferase (AST) and serum bilirubin levels within the normal reference range for the hospital laboratory. Normal serum alkaline phosphatase (ALP) levels were not required as many patients had radiological evidence of bone metastases. Creatinine clearance was estimated using the formula of Lott and Hayton ( 1980). Patients were treated with epirubicin 12.5-120 me m-3 iven as a slow bolus intravenous injection. Treatment dose was selected by the clinician. To reduce the possible bias of the older and less fit women being treated at lower doses. some of the younger patients were treated using divided doses. In these women the 'studv' dose of epirubicin was given on day 1 and the remainder administered 48 h later. after completing pharmacokinetic sampling. These patients were excluded from the pharmacodynamic analysis of myelosuppression. The following physical measurements A ere recorded: height. total body weight and surface area Ideal body weight ([BW) was calculated using the formula: IBW = 110 lb + 5 lb *Present address: ICRF Clinical Oncolog-s Unit Churchill Ho.spital. Old Road.
Many cytotoxic agents have a narrow therapeutic index and doses are routinely adjusted for surface area in adult patients. There remains. nevertheless. widespread variability in both clinical and pharmacokinetic outcome for patients treated with chemotherapy.
The sources of this variability are unclear and cast doubt on the usefulness of normalization for surface area as a means of optimizing treatment for individual patients.
In clinical practice. surface area adjustment is the single most widely used method of modifying dosage. Grochow et al (1990) evaluated dose modifications for a range of experimental and standard cytotoxics by correlating pharmacokinetic parameters with height. weight and surface area. Drug clearance correlated with only one measure (height) for a single cytotoxic. taxol. Reilly and Workman (1994) stated that '... normalisation of the dosage of antineoplastic drugs using either body weight or predicted surface area is actually of very limited value in producing consistent drug exposure'. Subsequently. a relationship was shown between clearance of both taxotere (Bruno et al. 1995) and oemcitabine (Allerheiligen et al. 1994 ) and surface area However. for most cytotoxics the use of surface area modification has not been evaluated.
The anthracyclines are among the most widely used cytotoxic agents. Liver dysfunction (Twelves et al. 1992) . gender (Wade et al. 1992 : Dobbs et al. 1995a ). obesity (Twelves et al. 1994 ) and age (Robert and Hoerni. 1983 ) have all been reported as influencing anthracycline pharmacokinetics. For over 20 years anthracycline doses have been modified in patients with abnormal liver tests -although the current recommended dose modifications may not be optimal (Twelves et al. 1992 : Dobbs et al. 1995b 
MATERIALS AND METHODS Patients and teatment
The study was approved by the local ethics committee and all patients gave written informed consent. Epirubicin pharmacokinetics were studied in 32 women with advanced breast cancer who had received no prior anthracycline treatment. Pharmacokinetics were studied during their first cycle of chemotherapy. All patients had normal liver biochemistry with serum aspartate aminotransferase (AST) and serum bilirubin levels within the normal reference range for the hospital laboratory. Normal serum alkaline phosphatase (ALP) levels were not required as many patients had radiological evidence of bone metastases. Creatinine clearance was estimated using the formula of Lott and Hayton ( 1980) . Patients were treated with epirubicin 12.5-120 me m-3 iven as a slow bolus intravenous injection. Treatment dose was selected by the clinician. To reduce the possible bias of the older and less fit women being treated at lower doses. some of the younger patients were treated using divided doses. In these women the 'studv' dose of epirubicin was given on day 1 and the remainder administered 48 h later. after completing pharmacokinetic sampling. These patients were excluded from the pharmacodynamic analysis of myelosuppression. 
Statistics
Variability in pharmacokinetic and pharmacodynamic end points was expressed as the coefficient of variation (CV%). Univariate analyses were used to investigate the relationship between physical or physiological characteristics and epirubicin pharmacokinetics or pharmacodynamics. In this data set correlation coefficients (r) as low as 0.3 are statistically significant. although they represent only a weak relationship. We defined values of r > 0.5 with P < 0.05 as significant in the context of this study. The relative importance of each individual parameter was evaluated using multivariate analysis. Mean percentage error (MPE) and mean absolute percentage error (MAPE) were calculated to assess the accuracy and precision respectively when comparing actual and predicted AUC and neutrophil nadirs.
RESULTS
The clinical and biochemical characteristics of all 32 patients are shown in Tables 1 and 2 respectively. All had normal liver serum transaminases and bilirubin.
In all patients the epirubicin concentration-time data fitted a triexponential model. There was wide variability in both unadjusted epirubicin clearance (mean 49.5 1 h-. range 17.7-91.7) and adjusted clearance (mean 30.5 1 h-1 m-2. range 11.1-58.0). There was. however. a linear relationship between total epirubicin dose and AUC (r = 0.80. P < 0.001).
Sources of variability in epirubicin clearance
The influence on variability in unadjusted clearance of epirubicin of the following factors was investigated: physical characteristics (surface area, height. total body weight. IBW%) and age. If adjustment for surface area is important. unadjusted epirubicin clearance should be positively correlated with surface area. Figure 1 shows that there was also no significant relationship between unadjusted epirubicin clearance and surface area (r = -0.12). Similarly, if surface area is a significant factor in determining epirubicin clearance, the variability in adjusted clearance should be less than that of total clearance. Over the dose range 12.5-120 mg, m-2 there was no difference in the variation of the adjusted and unadjusted epirubicin clearance (CV = 39.4%c and 37.7% respectively: P > 0.05). These data show that. whereas there is substantial variability in epirubicin clearance, this is not reduced by adjusting for surface area.
There was also no relationship between unadjusted epirubicin clearance and height (r = -0.01 . body weight (r = -0.15.) IBW%7
(r = -0.17). BMI (r = -0.16) or age (r =-0.12).
Impact of surface area dose adjustment on pharmacokinetics (AUC) observed AUC x mean dose (mg) Predicted AUC = Actual dose (mg) Table 4 shows the observed neutrophil nadir (resulting from the mg m-2 dose of epirubicin administered) and the predicted AUC (that would be expected had an unadjusted dose of epirubicin been given). The median observed and predicted nadirs were 1.07 and 0.96 x 109 1-'respectively. There was also no difference in the variability of the observed and predicted nadirs, both having CVs of 71%. The relationship between the observed and predicted neutrophil nadirs is shown in Figure 2 . The accuracy and precision of the predicted neutrophil count was confirmed by an MPE and MAPE of 4.5% and 11.6 respectively.
DISCUSSION
The most important finding in this paper is that there is no relationship between total plasma clearance of epirubicin and any clinical or biochemical parameter or physical characteristic, including body surface area. The implication of these data is that abandoning surface area normalization of epirubicin would not increase the variability in AUC, nor would it significantly affect neutropenia. a measure of epirubicin pharmacodynamics. These data support the smaller study by Cosolo et al (1994) who also reported no relationship between epirubicin clearance and surface area, although there did appear to be a correlation with lean body mass. Taken with work by Grochow et al (1990) these pharmacokinetic data cast serious doubts on the aptness of normalizing doses according to surface area. It is, however, pharmacodynamic parameters (response or toxicity) that are important in clinical practice. In the current study neutropenia was correlated with epirubicin AUC. Indeed, in a multivariate analysis AUC predicted the neutrophil nadir more strongly than dose of epirubicin or any physical or physiological variable. Other studies have also shown that myelosuppression is influenced by the AUC of epirubicin (Jakobsen et al, 1991) , doxorubicin (Ackland et al. 1989 ) and iododoxorubicin Twelves et al, 1994 characteristics may best be assessed by first using unadjusted drug doses. as for biochemical and haematological parameters. provided the patients surface area fell within normal limits'. As data on pharmacokinetics and toxicity are collected the determinants of variability should be studied svstematicallv. and. when appropriate. incorporated at higher dose levels in the phase I study. These data could then be confirmed by population pharmacokinetic studies in phase II trials.
The current study has shown that there is wide variability in epirubicin pharmacokinetics despite normalization of doses for surface area. Administration of fixed doses of epirubicin would not increase the variability in epirubicin AUC. Likewise. from a clinical perspective. it appears that fixed dosing would not significantlv alter the pattern of myelosuppression. There is a need to evaluate systematically the sources of variability in pharmacokinetics and pharmacodynamics in order to develop rational dose recommendations. In some cases this will involve surface area normalization but in others alternate dose strategies may be identified. These considerations apply to drugs in clinical use but are maybe even more relevant for agents under development.
